Carbonic anhydrase inhibitors: an editorial.
This issue of Expert Opinion on Therapeutic Patents is dedicated to carbonic anhydrase (CA, EC 4.2.1.1) inhibitors (CAIs), a highly dynamic research topic in the last years. Several review articles and patent analyses on diuretics and antiglaucoma, antiepileptic, anti-obesity and anticancer agents belonging to the pharmacological class of the CAIs are presented, together with a review on bacterial, fungal and protozoan CAs and their inhibition as a novel means of designing anti-infectives.